Skip to content
Review Open access

Metabolic reprogramming in pulmonary fibrosis: mechanisms and therapeutic perspectives

Oct 2026 · Frontiers in Medicine · Vol 13 · 0 citations · 107 references
Medicine

Abstract

Pulmonary fibrosis is a fatal disease characterized by progressive destruction of the lung parenchyma and excessive deposition of extracellular matrix, and is marked by a complex pathogenesis and limited treatment options. In recent years, metabolic reprogramming has emerged as a central mechanism by which cells adapt to stress and contribute to disease progression, attracting considerable interest within pulmonary fibrosis research. This review summarizes the metabolic reprogramming of key effector cells involved in pulmonary fibrosis, including lung fibroblasts, alveolar epithelial cells, macrophages, and endothelial cells, focusing on glucose, lipid, and amino acid metabolic pathways. It elucidates how these metabolic alterations drive fibrotic progression by influencing cell activation, proliferation, apoptosis, and intercellular communication. Building on these mechanistic insights, the review further summarizes potential therapeutic strategies targeting various metabolic pathways, aiming to establish a theoretical foundation and strategic directions for the development of novel precision therapies for pulmonary fibrosis. Furthermore, we highlight the metabolic communication among different pulmonary cell populations and discuss emerging challenges for precision metabolic therapies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.